CRNN抗体;CRNN Antibody—艾普蒂 新品

+ +

•  

   

     IHC-P analysis of esophagus tissue by CRNN antibody (P15141) IHC-P was performed using sections of the formalin-fixed paraffin-embedded esophagus tissue;Result: Squamous epithelial cells are positively stained at the cytoplasm.    

  
  

CRISPR-associated antibodies, often developed against key components like Cas9 or Cas12 enzymes, have emerged as critical tools in advancing CRISPR-based research and therapeutic applications. The CRISPR-Cas system, originally discovered as a bacterial adaptive immune mechanism, revolutionized genetic engineering due to its precision in genome editing. However, challenges such as off-target effects, immune responses, and the need for temporal control over editing activity prompted the development of antibodies targeting Cas proteins.

These antibodies serve multiple purposes. Neutralizing antibodies can inhibit Cas enzyme activity, providing a safety switch to halt unintended editing or mitigate immune reactions in therapeutic contexts. Detection antibodies enable the monitoring of Cas protein expression and localization, crucial for optimizing delivery systems (e.g., viral vectors or lipid nanoparticles) in gene therapies. Additionally, antibody-based purification methods facilitate the production of high-purity Cas proteins for research or clinical use.

In therapeutics, anti-Cas antibodies are explored to address immune-related hurdles, as pre-existing immunity against bacterial-derived Cas proteins may compromise treatment efficacy. They also aid in controlling editing timelines, enhancing precision in ex vivo applications like CAR-T cell engineering. As CRISPR technologies expand into diagnostics (e.g., CRISPR-based pathogen detection), antibodies against Cas enzymes further support assay development and standardization. Ongoing research focuses on improving antibody specificity, affinity, and compatibility with in vivo applications to fully harness CRISPR's potential while minimizing risks.